CA3165432A1 - Dosages and methods for treating pulmonary arterial hypertension with rodatristat - Google Patents
Dosages and methods for treating pulmonary arterial hypertension with rodatristat Download PDFInfo
- Publication number
- CA3165432A1 CA3165432A1 CA3165432A CA3165432A CA3165432A1 CA 3165432 A1 CA3165432 A1 CA 3165432A1 CA 3165432 A CA3165432 A CA 3165432A CA 3165432 A CA3165432 A CA 3165432A CA 3165432 A1 CA3165432 A1 CA 3165432A1
- Authority
- CA
- Canada
- Prior art keywords
- rodatristat
- ethyl
- compound
- amount
- rvt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062968651P | 2020-01-31 | 2020-01-31 | |
| US62/968,651 | 2020-01-31 | ||
| PCT/IB2021/000046 WO2021152398A1 (en) | 2020-01-31 | 2021-01-29 | Dosages and methods for treating pulmonary arterial hypertension with rodatristat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3165432A1 true CA3165432A1 (en) | 2021-08-05 |
Family
ID=75143674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3165432A Pending CA3165432A1 (en) | 2020-01-31 | 2021-01-29 | Dosages and methods for treating pulmonary arterial hypertension with rodatristat |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230074252A1 (https=) |
| EP (1) | EP4096633A1 (https=) |
| JP (1) | JP2023512025A (https=) |
| KR (1) | KR20220156813A (https=) |
| CN (1) | CN115379825A (https=) |
| AU (1) | AU2021212355A1 (https=) |
| CA (1) | CA3165432A1 (https=) |
| MX (1) | MX2022009254A (https=) |
| WO (1) | WO2021152398A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11413287B2 (en) | 2018-11-16 | 2022-08-16 | Altavant Sciences Gmbh | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension |
| WO2023062595A1 (en) * | 2021-10-14 | 2023-04-20 | Altavant Sciences Gmbh | Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl |
| WO2023079486A1 (en) * | 2021-11-03 | 2023-05-11 | Altavant Sciences Gmbh | Treatment of pulmonary arterial hypertension with rodatristat and ambrisentan |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| CA3119912A1 (en) * | 2018-11-14 | 2020-05-22 | Altavant Sciences Gmbh | A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin |
-
2021
- 2021-01-29 CN CN202180021555.2A patent/CN115379825A/zh not_active Withdrawn
- 2021-01-29 WO PCT/IB2021/000046 patent/WO2021152398A1/en not_active Ceased
- 2021-01-29 AU AU2021212355A patent/AU2021212355A1/en not_active Abandoned
- 2021-01-29 KR KR1020227030098A patent/KR20220156813A/ko not_active Withdrawn
- 2021-01-29 EP EP21713735.5A patent/EP4096633A1/en not_active Withdrawn
- 2021-01-29 JP JP2022546019A patent/JP2023512025A/ja active Pending
- 2021-01-29 MX MX2022009254A patent/MX2022009254A/es unknown
- 2021-01-29 US US17/759,700 patent/US20230074252A1/en not_active Abandoned
- 2021-01-29 CA CA3165432A patent/CA3165432A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021152398A1 (en) | 2021-08-05 |
| EP4096633A1 (en) | 2022-12-07 |
| AU2021212355A1 (en) | 2022-08-18 |
| JP2023512025A (ja) | 2023-03-23 |
| CN115379825A (zh) | 2022-11-22 |
| MX2022009254A (es) | 2022-09-07 |
| KR20220156813A (ko) | 2022-11-28 |
| US20230074252A1 (en) | 2023-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12370195B2 (en) | Oral compositions of MK2 pathway inhibitor for treatment of immune conditions | |
| JP6431478B2 (ja) | Ｂ型肝炎ウイルスのｃｃｃｄｎａの転写の調節 | |
| JP2023515817A (ja) | ダブラフェニブ、ｅｒｋ阻害剤及びｓｈｐ２阻害剤を含む三重の医薬品の組合せ | |
| CA3165432A1 (en) | Dosages and methods for treating pulmonary arterial hypertension with rodatristat | |
| KR20210094672A (ko) | Ｃｘｃｒ４ 길항제의 용도 | |
| US20190290627A1 (en) | Pim kinase inhibitor combinations | |
| JP2014132023A (ja) | 医薬組成物 | |
| US20210290651A1 (en) | Methods of treating viral infections using inhibitors of nucleotide synthesis pathways | |
| US20250090530A1 (en) | Combinations for the treatment of cancer | |
| RS64936B1 (sr) | Metodi lečenja hematoloških maligniteta korišćenjem 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benz il)amino-)izoindolin 1,3-diona | |
| HK40079142A (en) | Dosages and methods for treating pulmonary arterial hypertension with rodatristat | |
| US20250213550A1 (en) | Compounds and methods for treating inflammatory bowel disease | |
| WO2024102778A1 (en) | Pyrrolopyrimidine compositions for treatment of itk mediated conditions | |
| KR102497051B1 (ko) | 빅테그라비르의 대사물 | |
| AU2024250458A1 (en) | Psma-targeted radiopharmaceuticals and dna damage response inhibitor combination therapy | |
| Carbo Tutusaus et al. | American Chemical Society-251st National Meeting and Exposition. San Diego, California, USA-March 13-17, 2016 | |
| JP2025523817A (ja) | 慢性移植片対宿主病の治療におけるベルモスジル代謝産物及びその使用 | |
| Font et al. | American Chemical Society-255th National Meeting and Exhibition. New Orleans, Louisiana, USA-March 18-22, 2018 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220808 |